WillItSurvive
Pharma and healthcare groups · China

Luye Pharma Group

luye.cn ↗

Chinese pharma making long-acting CNS, oncology, and cardiovascular drugs via microsphere and liposome tech.

Protection under test
Assessed 26 July 2026 · Evidence as of 26 July 2026
Something worth protecting exists and is being tested right now.
On the recordSince 26 July 2026 · Checkable from 28 August 2026 · Every call on the record Checkpoint: H1 2026 results release, testing whether FY2025 profit recovery or H1 2025 profit drop is the real trend
The call

CNS and oncology growth is outrunning cardiovascular decline for now, while biosimilar competition and a Boan Biotech restructuring reshape what investors actually hold.

Luye Pharma makes specialty medicines in China, using technology to deliver drugs slowly through the body so patients need fewer shots. It is hard to copy because the company has FDA and European approval for its manufacturing and has built relationships with Chinese hospitals, but three things make this risky: other companies are selling cheaper versions of similar drugs, Luye's old heart medicines are selling much less than before, and new artificial intelligence tools at rival companies may discover new drugs faster than Luye can. The key question is whether Luye's newer medicines, especially brain and cancer drugs, can grow fast enough to replace the sales it is losing from older products, and whether a planned breakup of one of its business units will hurt the value of your investment.

Why
01
AI pressure: Insilico Medicine and AstraZeneca's AI-driven discovery platforms. AI-accelerated target discovery could let rivals move faster on new compounds, but no AI tool yet directly displaces Luye's manufacturing or filings. Could AI do the core job? Unlikely.
02
Bigger players: J&J (Invega Sustenna/Trinza) and six FDA-approved denosumab biosimilar rivals. Competing long-acting antipsychotics and a crowded biosimilar field for denosumab are already live and pricing pressure is building. Could a giant copy it? Probably.
03
What protects it. Proprietary microsphere and liposome delivery platforms plus FDA/EMA/NMPA manufacturing approval and entrenched China hospital distribution.
What would change this call
H1 2026 results (due 28 Aug 2026) show net profit trend vs H1 2025's -18.4% decline. Reveals whether FY2025 profit recovery or H1 2025 decline is the real trend.
Boan Biotech deconsolidation via exchangeable preference shares completes as filed. Shows how much group financials and asset base shrink post-restructuring.
LY03015 US Phase 2 readout and any FDA filing news through 2026. Tests whether Luye's US pipeline can offset legacy cardiovascular erosion.
Key numbers
  • FY2025 revenue RMB 6,308.4m, up 4.1% YoY (2025-12-31)
  • CNS revenue RMB 2,028.0m, up 25.7% YoY (2025-12-31)
  • Cardiovascular product revenue down 30.6% YoY (2025-12-31)
Named risks
  • Cardiovascular legacy product revenue eroding 30.6% YoY in FY2025 with no confirmed replacement growth. Severity: high
  • Boan Biotech exchangeable preference share structure could deconsolidate a majority-owned biologics subsidiary within about six months. Severity: medium
  • Denosumab biosimilar field already has six FDA-approved global rivals shipping, compressing pricing and share for Boan's assets. Severity: high
  • No disclosed AI adoption in R&D while multinational peers report large AI partnerships and faster discovery timelines. Severity: medium
  • No dividend declared for FY2025 despite profit growth could pressure investor sentiment on HKEX-listed shares. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
J&J (Invega Sustenna/Trinza)losing toJ&J's long-acting injectable antipsychotics already dominate the global market as of 2026, ahead of Luye's CNS injectables
Biocon, Hikma, Sandoz, Organon/Henlius, Celltrion, Samsung BioepiscontestingAll six received FDA denosumab biosimilar approvals between March 2024 and March 2026, crowding Boan Biotech's pipeline
Eli Lilly / Insilico Medicinelosing toLilly's $2.75bn AI drug discovery partnership announced around March 2026 outpaces Luye's undisclosed AI strategy
AstraZenecalosing toAstraZeneca claimed over 50% faster AI-driven target validation as reported January 2026, versus no public AI adoption by Luye
Hengrui Medicine, BeiGenecontestingCited as major Chinese oncology/CNS peers with broader pipelines, per 2026-04-03 analysis source
Questions people ask
Is Luye Pharma Group profitable?
Yes. Luye Pharma reported FY2025 net profit of RMB 705.7 million, up 9.4% year over year, on revenue of RMB 6,308.4 million and a 66.0% gross margin, per its annual results filed 2026-03-30 on HKEX.
Did Luye Pharma pay a dividend in 2025?
No. Despite FY2025 net profit rising 9.4% to RMB 705.7 million, Luye Pharma declared no dividend for the year, according to a 2026-03-30 announcement, a decision flagged as notable given the profit growth.
Who owns Luye Pharma Group?
Luye Pharma is HKEX-listed (02186); founder Liu Dian Bo, through Luye Investment Group, is cited as controlling shareholder at roughly 35% of shares as of early 2025 per an analysis source, with no parent company.
Could AI replace Luye Pharma's drug development?
Unlikely to fully replace it. Luye's moat is proprietary long-acting delivery formulations (microspheres, liposomes, patches), multi-country GMP approvals, and China hospital distribution, physical and regulatory assets AI does not directly displace as of 2026.
Is Luye Pharma's cardiovascular business struggling?
Yes. Luye's cardiovascular system products revenue declined about 30.6% year over year in FY2025 (year ended 2025-12-31), even as CNS revenue grew 25.7% and oncology grew 10.2% in the same period.
What is Luye Pharma's biggest competitive threat in biosimilars?
Crowded denosumab biosimilar competition: six rivals, including Biocon, Hikma, Sandoz, Organon/Henlius, Celltrion, and Samsung Bioepis, received FDA approvals between March 2024 and March 2026, per drugs.com data dated 2026-04-20.
Timeline
  • 2026-07-06Completed early redemption of US$180m 6.25% convertible bonds due 2028
  • 2026-06-16Reported positive China Phase 2 results for LY03015 in tardive dyskinesia
  • 2026-06-08Issued US$180m 5.25% convertible bonds due 2031, listed in Vienna
  • 2026-04-30First subject enrolled in China Phase 2 trial for LY03020
  • 2026-03-30FY2025 results: revenue RMB 6,308.4m, net profit RMB 705.7m, no dividend declared
  • 2026-01-27Completed sale of 25% minority stake in Nanjing Luye for RMB 1,086,383,600
  • 2026-01-16FDA approved supplemental NDA for Rykindo removing 12.5mg strength
  • 2026-01-11Boan Biotech exchangeable preference share structure disclosed, deconsolidation pending
  • 2025-08-28H1 2025 results: revenue up 3.5%, net profit down 18.4% year over year
  • 2025-04-30Rotigotine Luye transdermal patch launched in the UK
Revision history
26 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
SolventumNovo NordiskBaxter International
More in Pharma and healthcare groups →
Sources